Document jN3ooEdkb7kYYN4GwpEKoek3Z

To: From: Cc: Bcc: Received Date: Subject: George Woodall <Woodallg@api.org> a.r.schnatter@exxonmobil.com <a.r.schnatter@exxonmobil.com> 2002-05-2816:40:40 GMT FW: (API) Benzene study - June 5 confirmed A. Robert Schnatter Voice: 908-730-1101 Fax: 908-730-1192 Cell: 908-403-1270 Room LF-252 ExxonMobil Biomedical Sciences, Inc. 1545 Route 22 East Annandale, NJ 08801-0971 ----- Forwarded by A R Schnatter/East-US/ExxonMobil on 05/28/02 12:35 PM "Lorraine Twerdok" To: "Linda Williams (E-mail)" <WiliiamsL@api.org> <Twerdokl@api.o cc: "Patrick Beatty (E-mail)..<PWBE@chevrontexaco.com>. "Tom rg> Armstrong (E-mail)" <twarmst@erenj.com>, "Schnatter Rob (E-mail)" <a.r.schnatter@exxonmobil.com>, "Stuart Cagen (E-mail)" <szcagen@shellus.com>, "'richard. irons@uchsc. com' (E-mail)" 05/24/0212:12 <richard.irons@uchsc.com> PM Subject: FW: (API) Benzene study - June 5 confirmed Linda, Can you please call Jim Collins (phone number below) to find out the hotel we need to make reservations at in Detroit? I'll need a room for Tues. evening, June 4. I think you have my credit card number, but if not, you can have Buddy at Travel-on make the reservation - he's got the number for sure. Also, once you find out the hotel, can you please sent the information to Patrick Beatty, Tom Armstrong, Rob Schnatter, Rich Irons and Stuart Cagan? All are copied on this email to give you their email addresses. Thanks, Lorraine -----Original Message----From: Collins, Jim (JJ) [mailto:JJCollins@dow.com] Sent: Thursday, May 23,20029:04 AM To: Lorraine Twerdok; Hunt, David (DG) Cc: Tom Armstrong (E-mail); Patrick Beatty (E-mail); Irons, Richard (E-mail); Schnatter Rob (E-mail); Bloemen, Louis (LJ); Pottenger, Lynn (LH); Budinsky, Robert (RA); Kociba, Richard (RJ); Wrzesinski, Tiffany (T); Baase, Cathy (CM); Bodner, Kenneth (KM); Burns, Carol (CJ) Subject: RE: (API) Benzene study - June 5 confirmed SH ELL-MCCLU RG-055365 It looks like the morning of June 5th at the Detroit airport works best for everyone. I will have Tiffany arrange a meeting room at the hotel airport and send everyone the details. How is times 9-12? Will an overhead projector be all we need for the presentations? Is there anyone else I should include in this meeting? Tiffany, Please arrange a meeting room at the hotel airport in Detroit. I think it is Marriott. Let's tentatively set up the meeting for 9:00-12:00. This will give the Dow people time to drive in from Midland. We will also need an overhead and a phone, and a call in number for Midland and oversees participants. Cathy, We will be sitting down with the researchers on the Chinese benzene study to be briefed in detail about the protocol. You are welcome to attend. Jim James J. Collins, PhD Dow Chemical Company Epidemiology, Building 1803 Midland, Michigan 48674 Phone: (989) 636-1276 Fax: (989) 636-1875 Cell Phone: (989) 430-5914 email: jjcollins@dow.com -----Original Message----From: Lorraine Twerdok [mailto:Twerdokl@api.org] Sent: Wednesday, May 22,20021 :29 PM To: Collins, Jim (JJ) Cc: Tom Armstrong (E-mail); Patrick Beatty (E-mail); Irons, Richard (E-mail); Schnatter Rob (E-mail) Subject: (API) Benzene study - June 5 confirmed Hi JimJune 5th works for my group, too. As a matter of fact, I just sent an email to David suggesting the same date. I've attached the email, as an FYI. I'll try to get in touch (by phone) today or tomorrow to discuss further. Thanks, Lorraine ****************************** Lorraine E. Twerdok, Ph.D., DABT Manager, Health Sciences American Petroleum Institute SH ELL-MCCLU RG-055366 1220 L Street, NW. Washington, DC 20005 tel: 202-682-8344 fax: 202-682-8270 email: twerdokl@api.org <mailto:twerdokl@api.org> -----Original Message----From: Collins, Jim (JJ) [mailto:JJCollins@dow.com] Sent: Wednesday, May 22,20028:11 AM To: Lorraine Twerdok; Tom Armstrong (E-mail); Schnatter Rob (E-mail) Cc: Hunt, David (DG); Patrick Beatty (E-mail); Bloemen, Louis (LJ); Pottenger, Lynn (LH); Budinsky, Robert (RA); Kociba, Richard (RJ) Subject: RE: (API) Benzene study - June 4 won't work Tom/Lorraine/Rob, How about having the meeting in Detroit the morning of June 5th? This date works for most of us and we could either have the meeting at the airport or the Dow Automotive office. This would allow all to be on a plane by mid-day. Jim James J. Collins, PhD Dow Chemical Company Epidemiology, Building 1803 Midland, Michigan 48674 Phone: (989) 636-1276 Fax: (989) 636-1875 Cell Phone: (989) 430-5914 email: jjcollins@dow.com -----Original Message----From: Lorraine Twerdok [mailto:Twerdokl@api.org] Sent: Tuesday, May 21 , 2002 10: 13 AM To: Hunt, David (DG) Cc: Tom Armstrong (E-mail); Schnatter Rob (E-mail); Patrick Beatty (E-mail) Subject: RE: (API) Benzene study - June 4 won't work Importance: High David Thanks for your prompt response. I have been in touch with our exposure investigators, and June 4 will not work for them. Scheduling may take a little time, since Dr. Armstrong is spending quite a bit of time in Shanghai (he's there now). As soon as I receive a list of potential dates for a meeting (I think a meeting may required to address all of your concerns). We are of the same mind as you with regards to the information and the materials you will need to review in order to get an accurate assessment of SH ELL-MCCLU RG-055367 the reliability of the exposure numbers. Thus, we will provide you with more detailed information. Finally, thank you very much for enumerating your concerns in your email. With this information we can be fully prepared when we meet. I look forward to scheduling this meeting and further discussing the program. Regards, Lorraine Twerdok ****************************** Lorraine E. Twerdok, Ph.D., DABT Manager, Health Sciences American Petroleum Institute 1220 L Street, NW. Washington, DC 20005 tel: 202-682-8344 fax: 202-682-8270 email: twerdokl@api.org <mailto:twerdokl@api.org> -----Original Message----From: Hunt, David (DG) [mailto:DGHUNT@dow.com] Sent: Wednesday, May 15, 2002 11 :06 AM To: Lorraine Twerdok Cc: Patrick Beatty (E-mail); Stuart Cagen (E-mail); Tom Armstrong (E-mail); Andrew Jaques (E-mail); Bloemen, Louis (LJ); Budinsky, Robert (RA); Collins, Jim (JJ); Kociba, Richard (RJ); Pottenger, Lynn (LH); Baase, Cathy (CM); Bond, Gregory (GG) Subject: RE: (API) Benzene study Lorraine, it was nice to meet you again and to receive an update on the API Benzene study / Shanghai Health Study. I have checked, and we are interested in discussing the API Benzene study / Shanghai Health Study. As I had indicated we have significant concerns with this study, not only for how exposure will be handled, but also concerning other aspects. We have identified Tuesday, June 04,2002 (8:00 AM-1 0:00 AM EDT) as a time at which we can have our technical experts available for a presentation and discussion on this study. If you think that additional time is required, I can check on our further availability. We have also made arrangements for this to be a teleconference at our Midland headquarters so that both our US and European based colleagues can participate. We believe that in order to address the issues properly, this presentation should be more than just an overview of the project. I have distributed copies of the presentation you made at our BTX VCCEP meeting last week. We are interested in a presentation of the scientific aspects of the studies SH ELL-MCCLU RG-055368 (our understanding is that three are planned), the status of the project, the difficulties identified and met, a description of the project organization (committees), contacts, agreements and expectations for buy in from governmental agencies, and the options for participation. In addition we would want to gain an understanding of how the scientific understanding will be improved. Also are there opportunities for modifying aspects of the project to address specific concerns? Cost is also a concern, especially since the cost and scope of the project appears to have significantly increased from the initial inception. We have received information in the past concerning this project, both in the US and in Europe, and do not feel that these issues have been adequately addressed or explained. The following people representing expertise in toxicology and epidemiology are expected to attend for Dow: Louis Bloemen Robert Budinsky Jim Collins Richard Kociba Lynn Pottenger Please let me know if this proposal for a meeting on June 4, 2002, is agreeable, and if we need to discuss additional details for this meeting. Best Regards, David David Hunt The Dow Chemical Company Global EH&S Product Leader Hydrocarbons and Energy (HC&E) 989-636-0190 FAX: 989-636-9899 dghunt@dow.com * Trademark of The Dow Chemical Company -----Original Message----From: Lorraine Twerdok [mailto:Twerdokl@api.org] Sent: Friday, May 10, 2002 3:45 PM To: David Hunt (E-mail) Cc: Patrick Beatty (E-mail); Stuart Cagen (E-mail); Tom Armstrong (E-mail); Andrew Jaques (E-mail) Subject: (API) Benzene study Hi DavidNice to meet you at the VCCEP meeting on Wednesday. I would like to followup and facilitate setting up a meeting, at your convenience, to discuss exposure issues relating to the Shanghai Health Study. SH ELL-MCCLU RG-055369 I have a call into Tom Armstrong, the PI handling exposure for the studies, to suggest dates he could be available. Could you please check availability with your folks for the following first cut at dates? week of May 20th week of June 3rd week of june 10th Thanks, and I look forward to further discussions on this issue. Regards, Lorraine ****************************** Lorraine E. Twerdok, Ph.D., DABT Manager, Health Sciences American Petroleum Institute 1220 L Street, NW. Washington, DC 20005 tel: 202-682-8344 fax: 202-682-8270 email: twerdokl@api.org <mailto:twerdokl@api.org> SH ELL-MCCLU RG-055370 Location: Time: Call-in: Shanghai Health Study Technical Meeting with The Dow Chemical Company Jillle 5, 2002 Dow Automotive Auburn Hills, MI 8:30 - 11:00 AM TBD 8:30AM 8:35AM 8:45AM 9:05AM 9:15AM 9:35AM 10:50 AM 11:00 AM Introductions and Agenda Review Program Introduction and Background Scientific Overview Disease Progression Molecular Epidemiology Epidemiology Study Exposure Assessment Discussion Path Forward Adjourn L. Twerdok/All L. Twerdok R. Irons R. Schnatter/O. Wong T. Armstrong All L. Twerdok Research Program Attendees Investigators: Thomas Armstrong, ExxonMobil Biomedical Sciences, Inc. (exposure) Richard Irons, U. of CO (disease progression & molecular epidemiology) Robert Schatter, ExxonMobil Biomedical Sciences, Inc. (epidemiology) By phone: Otto Wong, Allied Health Sciences (epidemiology) Sponsor Representatives: Stuart Cagan, Shell Chemical By phone: Patrick Beatty, ChevronTexaco Consortium Administration: Lorraine Twerdok, American Petroleum Institute SHELL-MCCLURG-055371 Location: Time: Shanghai Health Study Technical Meeting with The Dow Chemical Company Jillle 5, 2002 Dow Automotive Auburn Hills, MI 8:30 - 11:00 AM Phone Conference # (domestic): 877-929-0361 International #: 712-923-4910 Participant Passcode: 899002 8:35AM 8:45AM Program Introduction and Background Scientific Overview Disease Progression Molecular Epidemiology L. Twerdok R. Irons Research Program Attendees Investigators: Thomas Armstrong, ExxonMobil Biomedical Sciences, Inc. (exposure) Richard Irons, U. of CO (disease progression & molecular epidemiology) Robert Schnatter, ExxonMobil Biomedical Sciences, Inc. (epidemiology) By phone: Otto Wong, Allied Health Sciences (epidemiology) Sponsor Representatives: Stuart Cagan, Shell Chemical By phone: Patrick Beatty, ChevronTexaco Consortium Administration: Lorraine Twerdok, American Petroleum Institute The Dow Chemical Company Representatives Jim Collins, Epidemiology Technical Leader David Hunt Dick Kociba, former Dow Toxicologist Bob Budinsky, Toxicologist By phone Louis Bloemen, Epidemiologist By phone Lynn Pottenger, Toxicologist SH ELL-MCCLU RG-055372